The 2025 annual meeting of the American Society of Hematology (ASH) recently concluded in Orlando, Florida. The four-day event featured hundreds of insightful sessions, educational presentations, and networking opportunities. The ASH annual meeting is recognized as the world's most comprehensive hematology event of the year.

Today, we have a curated selection of some of the thousands of abstracts presented during the ASH 2025 annual conference. The following abstracts and their associated summaries focus on diffuse large B-cell lymphoma (DLBCL) topics. Some descriptions and conclusions were edited for brevity and clarity. Visit the 2025 ASH meeting's abstracts page to view these abstracts and the thousands of others that were presented at the event.

Odronextamab Plus Chemotherapy in Patients with Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL): First Results From Part 1 of the Phase 3 Olympia-3 Study

  • Description: [The researchers] report on the first results from the dose escalation portion (1A) of the Phase 3, randomized, open-label, multicenter study OLYMPIA-3 (NCT06091865), the first to investigate whether Odro + chemotherapy (CHOP) is superior to standard-of-care rituximab + CHOP in patients with previously untreated DLBCL.
  • Conclusion: The safety profile of Odro-CHOP induction was generally manageable, with no new safety signals. Preliminary efficacy of this simplified regimen was encouraging, with a complete response rate of 100% for dose-level 2 (160 mg), suggesting that rituximab may not be required to achieve depth of response when combining Odro with CHOP in previously untreated patients with DLBCL.

Sasp-driven Immune Evasion Defines a Novel African Ancestry-Associated DLBCL Subtype with Distinctive Molecular and Immune Vulnerabilities

  • Description: Diffuse large B-cell lymphoma arises at an earlier age and is associated with inferior survival in African American patients. These disparities reflect socioeconomic and genetic factors.
  • Conclusion: [Researchers] identified a novel DLBCL subtype almost entirely restricted to [patients with African ancestry], driven by a novel senescence-associated secretory phenotype-like program that promotes lymphomagenesis via CD4 exhaustion. This subtype is readily diagnosed by IHC or flow cytometry using validated senescence markers.

Transcriptional Profiling Refines DLBCL Classification and Identifies Subtypes with Distinct Therapeutic Vulnerabilities

  • Description: To address [the limitations of using LymphGen (LG) for genetic classification of DLBC], [researchers] developed LymphGen-sig (LG-sig), a gene expression platform that extends conventional LG classification. To evaluate its clinical utility, [they] assessed the impact of LG-Sig classification on progression-free survival (PFS) in the POLARIX study (NCT03274492).
  • Conclusion: LymphGen-sig is a novel gene expression-based platform that complements conventional genetic classification by expanding subtype assignment to include previously unclassified cases, reassigning A53 DLBCLs into potentially more biologically relevant subtypes, and uncovering a subset of LymphGen-unclassified DLBCLs that derive benefit from pola-R-CHP treatment.

Characterization of Two Genetically Distinct Subtypes of C5 Diffuse Large B-cell Lymphoma (DLBCL)

  • Description: Diffuse large B-cell lymphoma (DLBCL) is a clinically and molecularly heterogeneous disease with two recognized transcriptional subtypes, activated B-cell (ABC) and germinal center B-cell (GCB) types. Comprehensive genomic profiling, by us and others, identified at least 5 genetically defined subtypes with specific genetic signatures and associated molecular-driven vulnerabilities, providing the ability to develop biology-informed treatments.
  • Conclusion: [The] study identified and independently validated the presence of two genetically distinct C5 DLBCL subtypes, C5A and C5B, both with inferior prognosis to R-CHOP treatment. The genetic, transcriptomic, and spatial proteomic differences between C5A/B suggest different underlying pathogenetic mechanisms in these two subtypes, potentially reflecting distinct therapeutic vulnerabilities.

Ibrutinib plus R-CHOP followed by maintenance in untreated ABC-DLBCL patients with IPI ≥2: A first analysis of phase II Study FIL RI-CHOP

  • Description: The FIL_RI-CHOP trial aims to assess whether combining R-CHOP-I, followed by ibrutinib maintenance, is safe and improves PFS in young, untreated patients with high-risk ABC DLBCL.
  • Conclusion: Findings demonstrate that central pathology review and NanoString’s LST COO assessment are feasible without delaying treatment initiation. The addition of ibrutinib to R-CHOP appears feasible and effective, achieving >70% metabolic CR with a manageable safety profile in young, high-risk ABC-DLBCL patients.

Fixed Treatment Duration Subcutaneous Mosunetuzumab Monotherapy in Elderly/unfit Patients with Previously Untreated Diffuse Large B-cell Lymphoma: Interim Results from the Phase II MorningSun Study

  • Description: The Phase II MorningSun study is the first to assess the efficacy and safety of subcutaneous (SC) Mosun monotherapy in elderly/unfit patients with previously untreated DLBCL. [The researchers] report an interim analysis for this study.
  • Conclusion: There remains an unmet need for effective chemotherapy-free options in previously untreated elderly and CIT-ineligible patients with DLBCL. Interim data from MorningSun demonstrate that fixed-duration Mosun SC monotherapy is active in these patients, with promising efficacy and a manageable safety profile, with predominantly mild-to-moderate AEs, allowing for outpatient administration in the community practice setting.

Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2025 Guideline Central, all rights reserved.